Merck & Company Inc (MRK) is a publicly traded drug manufacturers-general business based in the US. It opened the day at $107.22 after a previous close of $106.73. During the day the price has varied from a low of $105.96 to a high of $107.22. The latest price was $106.34 (25 minute delay). Merck & Co. is listed on the NYSE and employs 67,000 staff. All prices are listed in US Dollars.
Best for
0% commission
Best for
Beginner investments
Best for
Beginners
Best for
Low fees
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Customer rating | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|---|
|
★★★★★ | £0 - £9.99 | No minimum | £2.56 £436.96 total |
Capital at risk |
|
★★★★★ | £0 | $50 | £2.17 £436.57 total |
Capital at risk |
|
★★★★★ | £0 | £250 | £10.38 £444.78 total |
Capital at risk |
 |
Not yet rated | £0 | No minimum | £2.17 £436.57 total |
Capital at risk |
 |
Not yet rated | £0 | No minimum | £2.17 £436.57 total |
Capital at risk |
 |
★★★★★ | £0 | £1 | £16.29 £450.69 total |
Capital at risk |
|
Not yet rated | £0 | No minimum | £1.60 £436.00 total |
Capital at risk |
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Only you can make the decision on the time to leap. The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Merck & Co. P/E ratio, PEG ratio and EBITDA
Merck & Co.'s current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 87x. In other words, Merck & Co. shares trade at around 87x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Merck & Co.'s "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.359. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merck & Co.'s future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Merck & Co.'s EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $12.3 billion (£10.1 billion).
The EBITDA is a measure of a Merck & Co.'s overall financial performance and is widely used to measure a its profitability.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Merck & Co..
Merck & Co.'s total ESG risk: 28.35
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Merck & Co.'s overall score of 28.35 (as at 01/01/2019) is nothing to write home about – landing it in it in the 47th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Merck & Co. is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Merck & Co.'s environmental score: 3.15/100
Merck & Co.'s environmental score of 3.15 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck & Co. is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Merck & Co.'s social score: 15.55/100
Merck & Co.'s social score of 15.55 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck & Co. is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Merck & Co.'s governance score: 12.65/100
Merck & Co.'s governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Merck & Co. is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Merck & Co.'s controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Merck & Co. scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Merck & Co. hasn't always managed to keep its nose clean.
Join 50,000 subscribers who are notified about expert share tips. Plus a chance to win £500!
By signing up you agree to receive emails from Finder and to the privacy policy and terms & conditions.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Ever wondered how to buy shares in Exelixis? We explain how and compare a range of providers that can give you access to many brands, including Exelixis.
Ever wondered how to buy shares in Five Star Senior Living? We explain how and compare a range of providers that can give you access to many brands, including Five Star Senior Living.
Ever wondered how to buy shares in Community Health Systems? We explain how and compare a range of providers that can give you access to many brands, including Community Health Systems.
Ever wondered how to buy shares in Chiasma? We explain how and compare a range of providers that can give you access to many brands, including Chiasma.
Ever wondered how to buy shares in Healthcare Services Group? We explain how and compare a range of providers that can give you access to many brands, including Healthcare Services Group.
Ever wondered how to buy shares in Catalent? We explain how and compare a range of providers that can give you access to many brands, including Catalent.
Ever wondered how to buy shares in Aytu BioScience? We explain how and compare a range of providers that can give you access to many brands, including Aytu BioScience.
Ever wondered how to buy shares in bluebird bio? We explain how and compare a range of providers that can give you access to many brands, including bluebird bio.
Ever wondered how to buy shares in LHC Group? We explain how and compare a range of providers that can give you access to many brands, including LHC Group.
Ever wondered how to buy shares in Amneal Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Amneal Pharmaceuticals.